Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2016-03-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
西南证券股份有限公司关于公司2016年度预计日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Southwest Securities Co., Ltd. regarding the 2016 expected routine related-party transactions of Proya Pharmaceutical Co., Ltd. It includes transaction categories, amounts, related parties, pricing principles, approval procedures, independent directors' opinions, and the sponsor's verification opinion. The content focuses on the verification and opinions about related-party transactions for the fiscal year 2016. It is not a full annual report or interim financial report but a specialized audit or verification report related to regulatory compliance and related-party transactions. The document length is 7690 characters, which is substantial and contains detailed substantive content, not just an announcement or certification. Therefore, it fits best under Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles or regulatory compliance verifications excluding full annual reports. FY 2016
2016-03-24 Chinese
独立董事2015年度述职报告（潘亚岚）
Board/Management Information Classification · 95% confidence The document is a 2015 annual performance report of an independent director of a company, detailing attendance at board and shareholder meetings, independent opinions on various board resolutions, and other duties performed during the year. It references compliance with company law, securities law, and stock exchange rules, and includes detailed descriptions of the director's activities and opinions on corporate governance matters. The document is not a full annual report or financial statement but rather a management or governance-related report focusing on the independent director's role and activities. This fits best under Board/Management Information (MANG), which covers announcements related to changes or reports from company directors or senior management. The document length is 1714 characters, which is relatively short and focused on director duties rather than financial data or audit results, so it is not an Annual Report (10-K), Audit Report (AR), or Management Report (MDA). It is also not a Regulatory Filing (RNS) as it is a substantive report on director activities. Therefore, the classification is MANG with high confidence.
2016-03-24 Chinese
2016年日常关联交易预计公告
Regulatory Filings Classification · 95% confidence The document is titled as a 2016 daily related party transaction forecast announcement by 普洛药业股份有限公司. It details expected related party transactions, amounts, counterparties, and includes independent directors' opinions on the fairness and necessity of these transactions. It references compliance with stock exchange listing rules and company law. The document is a detailed announcement about expected related party transactions for the year, not a full financial report or audit. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS). The document length is over 13,000 characters, so it is not a mere report publication announcement. It contains substantive content about related party transactions and their governance, but no financial statements or audit opinions. Therefore, the best classification is Regulatory Filings (RNS).
2016-03-24 Chinese
第六届董事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of various reports and proposals related to the 2015 fiscal year, including the 2015 Annual Report, Board Work Report, General Manager Work Report, Financial Work Report, and Profit Distribution Plan. It also mentions the need for these to be submitted to the shareholders' meeting for approval. The document is a formal announcement of board meeting decisions rather than the full annual report itself. The length is short (1918 characters), and it references other detailed reports and announcements separately. Therefore, this document fits best as a Regulatory Filing (RNS) because it is an official announcement of board resolutions and approvals, not the full Annual Report or other detailed reports themselves.
2016-03-24 Chinese
关于提前年报披露时间的公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement from a company about the advancement of the disclosure date for its 2015 annual report. It states the original and new dates for the report release but does not contain the report itself or any financial data. The document length is only 373 characters, indicating it is a brief notice. According to the 'MENU VS MEAL' rule, such a short announcement about report timing is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2016-03-23 Chinese
关于召开2016年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2016 first extraordinary general meeting of shareholders for 普洛药业股份有限公司. It includes information on the meeting date, voting procedures (both in-person and online), agenda items (such as the election of an independent director), registration details, and proxy voting instructions. There are no financial statements or financial performance data included. The document serves as a notice and instructions for shareholders to participate in the meeting and vote on proposals. It is not a report of the meeting results, nor is it a full annual or interim report, earnings release, or any other financial report. Given the content and purpose, this document fits the category of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation of proxies or detailed information statements, it aligns best with a Proxy Solicitation & Information Statement (PSI). The document length is 4523 characters, which is consistent with a detailed meeting notice and proxy materials. Therefore, the classification is PSI with high confidence.
2016-03-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.